In adults with type 2 diabetes, a systematic review of preference studies found some preference for dipeptidyl peptidase-4 inhibitors over once daily liraglutide.
In plain wordsIn adults with type 2 diabetes, some studies found some patients preferred DPP-4 inhibitors to once daily liraglutide.
- Peptide
- Liraglutide
- Outcome
- Not applicablePatient preference versus DPP-4 inhibitors
- Study
n: not reported in source
- Comparator
- DPP-4 inhibitors
- Outcome group
- Patient-reported outcomes · Metabolic and weight
Source sentences
Among studies comparing GLP-1 RA to other glucose-lowering medications, some preferences were observed for dypeptil peptidase-4 inhibitors compared with once daily liraglutide.
1 context sentence(design, population, supporting numbers)
17 studies (7296 patients) proved eligible.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.